Home Diabetes Care Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Reasonably priced

Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Reasonably priced

Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Reasonably priced


Mark Cuban’s Cost Plus Drug Company is now offering medications from a big drug manufacturer on to individuals with diabetes at a reduced cost, a noteworthy development that proves the American billionaire entrepreneur can disrupt the pharmaceutical supply chain.

In a tweet on April 3, 2023, the corporate announced it’s selling branded medications for type 2 diabetes from Janssen, a unit at Johnson & Johnson. The medications include Invokana® (Canagliflozin), Invokamet® (Canagliflozin-Metformin HCl) and Invokamet® XR (Canagliflozin-Metformin HCl).  

The agreement with Johnson & Johnson marks the primary time that a brand-name drugmaker has agreed to offer medications through Cost Plus Drugs. Vice President of Trade Relations and Pharmaceutical Contracting Ray Risman said this partnership demonstrates that there’s a path forward for Cost Plus Drugs and single-source branded products. “It shows we are able to partner with top-tier pharmaceutical corporations with transparency and produce meaningful savings to those in need,” expanded Risman.

Cost Plus Drugs CEO and co-founder, Dr. Alex Oshmyanksy, added how the corporate is prioritizing products for individuals with diabetes. The recently added SGLT-2s are a more moderen class of treatments which have clinically shown to have meaningful advantages for individuals with type 2 diabetes, including reducing the danger of other comorbid conditions. With Cost Plus Drugs offering Invokana at a cheaper price, it will possibly improve access to SLGT-2 and its medical advantages to over 30 million Americans living with diabetes today.  

They intend so as to add other medications as well—including GLP-1s, continuous glucose monitors (CGMs), insulins, and DPP4s

Unfortunately, Americans with diabetes have suffered from artificially inflated drug and provide prices for much too long” Dr. Oshmyansky stated. “As a diabetic myself, I’ve experienced this issue first-hand, so adding more products for individuals with diabetes, at reasonable prices, is a top priority for us.”

Cost Plus Drugs can be exploring ways to proceed to bring inexpensive insulin to the broader patient population with a straightforward user experience, in light of the recent price reductions announced by Lilly, Novo Nordisk, and Sanofi.

One other initiative that the corporate is testing to bring more value to its users is the Team Cuban Card. The Team Cuban card will allow people to get Cost Plus Drugs’ low prices from their local pharmacy. This just isn’t only an added convenience but might help save individuals with diabetes the additional cost of costly cold-chain shipping from other mail-order pharmacies.

The value for Invokana at Cost Plus Drugs is $244 for a 30-day supply—a 50% savings in comparison with other direct-to-consumer pharmacy services or coupon vendors. It is on the market at costplusdrugs.com now for anybody who needs it.

Editor’s Note: Individuals who take insulin require consistently inexpensive and predictable sources of insulin in any respect times. For those who or a loved one are struggling to afford or access insulin, click here.


Please enter your comment!
Please enter your name here